-+ 0.00%
-+ 0.00%
-+ 0.00%
AlphaValue/Baader Europe Says Roche's Pipeline Delivery Offers Answers to Upcoming Patent Cliffs
Share
Listen to the news
12:33 AM EST, 11/18/2026 (MT Newswires) -- AlphaValue/Baader Europe believes Roche (RO.SW) improved pipeline delivery ahead of anticipated patent cliffs while avoiding "major" research and development setbacks compared with its peers. "The baton from subcutaneous-and-intravenously administered multiple sclerosis market leader Ocrevus (c.11% of sales; exclusivity until 2028-29) should be picked up by oral pill fenebrutinib (expected to be approved in 2027). While the next three-to-five years may also see the haemophilia leader Hemlibra (c.8%) and cancer treatment Tecentriq (c.6%) losing patents, Roche may find solutions in the strong momentum of the blood cancer portfolio, the newly approved breast cancer drug Giredestrant, and the late-stage candidates in Alzheimer's, Parkinson's, MASH, Hypertension and the lucrative obesity space. At the same time, we also acknowledge the risks involved in the late-stage trials in hard-to-crack areas of Alzheimer's and Parkinson's," according to a Tuesday note. Accordingly, the research firm raised the Swiss drugmaker's price target to 414 francs from 388 francs. On the other hand, AlphaValue/Baader Europe said Roche's valuations offer no room for material upside, adding that "waiting for sentiment-driven corrections seems like a good idea to play Roche." The stock has a reduce rating at the research firm.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending